Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 6/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.41 |
| ▸ | FURIN | P09958 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22138818 | 0.98 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL18911016 | 0.98 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL20841069 | 0.98 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL24335319 | 0.93 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL21230049 | 0.93 | SIRT2 (0.43) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL25009841 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL21466014 | 0.92 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL23106380 | 0.92 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL23789221 | 0.92 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3FURIN | |
| SCHEMBL21568762 | 0.92 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| US-20200362054-A1 | TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENTS AND USE THEREOF | NOVARTIS AG (CH) | 2020-11-19 | — | — | US | disclosed |
| US-20190099431-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190099431-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | SIRT2 4097/4885SIRT1 4465/4885SIRT5 2607/4885 |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | SIRT2 4861/4885SIRT1 4855/4885SIRT5 4480/4885 |
| US-20200362054-A1 | TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENTS AND USE THEREOF | CD2, CD2BP2, CD22 | SIRT2 4865/4885SIRT1 4876/4885SIRT5 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.